all bombay times print stories are available on
.jeffrey krasner is president of emerging biocommunications, which consults to early- and mid-stage life science companies.
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.